HOENIGL, M., J. SALMANTON-GARCIA, T. J. WALSH, M. NUCCI, C. F. NEOH, J. D. JENKS, M. LACKNER, R. SPRUTE, A. M. S. AL-HATMI, M. BASSETTI, F. CARLESSE, Tomáš FREIBERGER, P. KOEHLER, T. LEHRNBECHER, A. KUMAR, J. PRATTES, M. RICHARDSON, S. REVANKAR, M. A. SLAVIN, J. STEMLER, B. SPIESS, S. J. TAJ-ALDEEN, A. WARRIS, P. C. Y. WOO, J. A. H. YOUNG, K. ALBUS, D. ARENZ, V. ARSIC-ARSENIJEVIC, J. P. BOUCHARA, T. R. CHINNIAH, A. CHOWDHARY, G. S. DE HOOG, G. DIMOPOULOS, R. F. DUARTE, P. HAMAL, J. F. MEIS, S. MFINANGA, F. QUEIROZ-TELLES, T. F. PATTERSON, G. RAHAV, T. R. ROGERS, C. ROTSTEIN, R. WAHYUNINGSIH, D. SEIDEL and O. A. CORNELY. Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology. Lancet Infectious Diseases. Oxford: Elsevier SCI LTD, 2021, vol. 21, No 8, p. "E246"-"E257", 12 pp. ISSN 1473-3099. Available from: https://dx.doi.org/10.1016/S1473-3099(20)30784-2.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology
Authors HOENIGL, M. (guarantor), J. SALMANTON-GARCIA, T. J. WALSH, M. NUCCI, C. F. NEOH, J. D. JENKS, M. LACKNER, R. SPRUTE, A. M. S. AL-HATMI, M. BASSETTI, F. CARLESSE, Tomáš FREIBERGER (203 Czech Republic, belonging to the institution), P. KOEHLER, T. LEHRNBECHER, A. KUMAR, J. PRATTES, M. RICHARDSON, S. REVANKAR, M. A. SLAVIN, J. STEMLER, B. SPIESS, S. J. TAJ-ALDEEN, A. WARRIS, P. C. Y. WOO, J. A. H. YOUNG, K. ALBUS, D. ARENZ, V. ARSIC-ARSENIJEVIC, J. P. BOUCHARA, T. R. CHINNIAH, A. CHOWDHARY, G. S. DE HOOG, G. DIMOPOULOS, R. F. DUARTE, P. HAMAL, J. F. MEIS, S. MFINANGA, F. QUEIROZ-TELLES, T. F. PATTERSON, G. RAHAV, T. R. ROGERS, C. ROTSTEIN, R. WAHYUNINGSIH, D. SEIDEL and O. A. CORNELY.
Edition Lancet Infectious Diseases, Oxford, Elsevier SCI LTD, 2021, 1473-3099.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30303 Infectious Diseases
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 71.421
RIV identification code RIV/00216224:14110/21:00123978
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1016/S1473-3099(20)30784-2
UT WoS 000680046200004
Keywords in English rare mould infections; diagnosis; management
Tags 14110114, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 29/3/2022 12:42.
Abstract
With increasing numbers of patients needing intensive care or who are immunosuppressed, infections caused by moulds other than Aspergillus spp or Mucorales are increasing. Although antifungal prophylaxis has shown effectiveness in preventing many invasive fungal infections, selective pressure has caused an increase of breakthrough infections caused by Fusarium, Lomentospora, and Scedosporium species, as well as by dematiaceous moulds, Rasamsonia, Schizophyllum, Scopulariopsis, Paecilomyces, Penicillium, Talaromyces and Purpureocillium species. Guidance on the complex multidisciplinary management of infections caused by these pathogens has the potential to improve prognosis. Management routes depend on the availability of diagnostic and therapeutic options. The present recommendations are part of the One World-One Guideline initiative to incorporate regional differences in the epidemiology and management of rare mould infections. Experts from 24 countries contributed their knowledge and analysed published evidence on the diagnosis and treatment of rare mould infections. This consensus document intends to provide practical guidance in clinical decision making by engaging physicians and scientists involved in various aspects of clinical management. Moreover, we identify areas of uncertainty and constraints in optimising this management.
PrintDisplayed: 22/7/2024 02:33